For research use only. Not for therapeutic Use.
GSK2983559（Cat No.:I017900）, also known as compound 3, RIP2 kinase inhibitor 1, or RIPK2-IN-1, is a potent inhibitor of receptor interacting protein 2 (RIP2) kinase. It demonstrates high kinase specificity, meaning it selectively targets RIP2 kinase without significant interference with other kinases. By inhibiting RIP2 kinase activity, GSK2983559 may modulate signaling pathways associated with innate immune responses and inflammatory processes.
| Catalog Number | I017900 |
| CAS Number | 1579965-12-0 |
| Molecular Formula | C₂₁H₂₃N₄O₇PS₂ |
| Purity | ≥95% |
| Storage | Store at -20°C |
| IUPAC Name | 2-[4-(1,3-benzothiazol-5-ylamino)-6-tert-butylsulfonylquinazolin-7-yl]oxyethyl dihydrogen phosphate |
| InChI | InChI=1S/C21H23N4O7PS2/c1-21(2,3)35(29,30)19-9-14-15(10-17(19)31-6-7-32-33(26,27)28)22-11-23-20(14)25-13-4-5-18-16(8-13)24-12-34-18/h4-5,8-12H,6-7H2,1-3H3,(H,22,23,25)(H2,26,27,28) |
| InChIKey | MJLYDVMFNHZMLV-UHFFFAOYSA-N |
| SMILES | CC(C)(C)S(=O)(=O)C1=C(C=C2C(=C1)C(=NC=N2)NC3=CC4=C(C=C3)SC=N4)OCCOP(=O)(O)O |
| Reference | [1]. Haile PA, et al. Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases. J Med Chem. 2019 Jul 25;62(14):6482-6494. |
